Femasys (NASDAQ:FEMY) Given Buy Rating at HC Wainwright

HC Wainwright reaffirmed their buy rating on shares of Femasys (NASDAQ:FEMY) in a report issued on Tuesday,Benzinga reports. They currently have a $12.00 price objective on the stock.

Separately, Chardan Capital decreased their price target on Femasys from $12.00 to $10.00 and set a “buy” rating on the stock in a research note on Wednesday, August 14th.

Femasys Stock Down 11.6 %

FEMY opened at $1.03 on Tuesday. Femasys has a 12 month low of $0.73 and a 12 month high of $2.40. The company has a current ratio of 6.47, a quick ratio of 5.93 and a debt-to-equity ratio of 0.43. The business’s 50-day moving average price is $1.16 and its 200-day moving average price is $1.15. The company has a market cap of $22.90 million, a P/E ratio of -1.24 and a beta of -2.83.

Hedge Funds Weigh In On Femasys

An institutional investor recently raised its position in Femasys stock. CM Management LLC raised its holdings in shares of Femasys Inc. (NASDAQ:FEMY) by 6.3% in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 425,000 shares of the company’s stock after purchasing an additional 25,000 shares during the period. CM Management LLC owned 1.91% of Femasys worth $484,000 at the end of the most recent reporting period. Institutional investors own 65.27% of the company’s stock.

About Femasys

Femasys Inc, a biomedical company, develops therapeutic and diagnostic solutions to address unmet women healthcare needs worldwide. The company provides FemVue saline-air device, a contrast-generating product in the United States, Canada, Japan, and Hong Kong; FemCath, a cornual balloon catheter, a single intrauterine directional delivery product that allows for selective evaluation of an individual fallopian tube; and FemCerv, a biopsy device for endocervical curettage, which can be used to sample cervical cells and tissue circumferentially with sample containment within the device to minimize contamination.